DEF 14A: Reviva Pharma Seeks Shareholder Vote on Reverse Split, Capital Increase

Reviva Pharmaceuticals Holdings, Inc. calls its Annual Meeting to vote on a reverse stock split to maintain Nasdaq listing, an increase in authorized shares, and director elections.

Summary

• The Annual Meeting of Stockholders will be held virtually on Thursday, December 18, 2025, at 11:00 a.m. Pacific Time.
• Stockholders will vote on the election of five director nominees to serve until the next annual meeting.
• A proposal to ratify the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the year ending December 31, 2025, will be presented.
• An advisory vote on the executive compensation of the company's named executive officers is on the agenda.
• Shareholders will vote on an amendment to increase the authorized shares of common stock from 315,000,000 to 515,000,000.
• A proposal to adopt and approve an amendment to effect a reverse stock split of common stock, at a ratio ranging from one-for-two (1:2) to one-for-twenty (1:20), at any time prior to December 31, 2026, is also up for vote.
• The Board of Directors recommends voting FOR all proposals.

Sentiment

Score: 3

Explanation: The company faces significant challenges, including a Nasdaq delisting threat due to a low share price, persistent net losses, and a 'going concern' warning in its audit reports. While the proposed reverse stock split aims to address the listing issue, its effectiveness is uncertain, and it carries risks of further liquidity reduction and potential future delisting without a compliance period. The request for a substantial increase in authorized shares, while necessary for future capital, signals ongoing dilution risk for existing shareholders given the company's need for additional funding. The declining Total Shareholder Return further underscores poor performance. These factors collectively point to a high-risk investment with a negative outlook.

Positives

• The Board believes that the proposed actions, including the reverse stock split and increase in authorized shares, are advisable and in the best interests of the Company and its stockholders.
• The Board believes the company's compensation policies and practices are effective in motivating executive officers, enhancing long-term stockholder value, and attracting/retaining high-quality talent.
• The Audit Committee has determined that its members are independent and that Mr. Funtleyder qualifies as an audit committee financial expert.
• The company has adopted a Code of Business Conduct and Ethics, an Insider Trading Policy, and an Anti-Hedging Policy to promote compliance and good governance.

Negatives

• The company received a Nasdaq notice on May 13, 2025, indicating non-compliance with the $1.00 Minimum Bid Price Requirement for continued listing.
• As of October 21, 2025, the company's common stock closed at $0.52 per share on Nasdaq, significantly below the minimum requirement.
• Audit reports from Moss Adams LLP for the fiscal years ended December 31, 2024, and 2023, contained an explanatory paragraph regarding a going concern uncertainty.
• The company reported significant net losses: $29,918,802 in 2024, $39,260,837 in 2023, and $28,261,442 in 2022.
• Total Shareholder Return (TSR) based on a $100 initial investment on December 31, 2021, declined to $62.63 by 2024, from $178.20 in 2023 and $147.06 in 2022.
• The company has experienced changes in its independent registered public accounting firm, with Armanino LLP declining re-appointment in 2023 and Moss Adams LLP merging into Baker Tilly US, LLP in 2025.

Risks

• Failure to approve the reverse stock split may lead to delisting from Nasdaq, potentially resulting in trading on less efficient markets (OTC Bulletin Board or pink sheets), decreased liquidity, and avoidance by retail and institutional investors.
• There is no assurance that the proposed reverse stock split will increase the price of common stock or maintain compliance with Nasdaq listing standards for a sustained period.
• The market price of common stock after a reverse stock split may not rise proportionally to the reduction in shares or attract brokers and investors who avoid lower-priced stocks.
• Even if the reverse stock split is implemented, the market price may decrease due to factors unrelated to the split, and a decline could be a greater percentage than without the split.
• The proposed reverse stock split may decrease the liquidity of common stock due to the reduced number of outstanding shares.
• Under amended Nasdaq rules, if a reverse stock split is implemented and the company subsequently fails the Minimum Bid Price Requirement within one year, Nasdaq may proceed with delisting without providing any compliance period.
• Future issuance of additional shares of common stock (following the proposed increase in authorized shares) could have a dilutive effect on earnings per share, book value per share, and voting rights of existing stockholders.
• The issuance of authorized but unissued shares could potentially be used to deter a hostile takeover, which might otherwise be beneficial to stockholders.

Future Outlook

The company intends to use the additional authorized shares of common stock for various business and financial purposes, including raising capital through offerings, expanding business via strategic transactions (mergers, acquisitions, licensing), establishing strategic relationships, exchanging securities, and providing equity incentives to attract and retain talent. The reverse stock split is expected to increase the market price of common stock to regain and maintain Nasdaq listing compliance, improve marketability and liquidity, and potentially attract a broader range of institutional investors and analyst interest. The Board reserves the right not to proceed with either the increase in authorized shares or the reverse stock split, even if approved by stockholders.

Management Comments

• Our Board believes that the Director Election Proposal, Auditor Ratification Proposal, Say-on-Pay Proposal, Increase in Authorized Proposal, Reverse Stock Split Proposal, and Adjournment Proposal are each advisable and in the best interests of the Company and its stockholders.
• Our Board strongly believes that the Reverse Split is necessary to maintain our listing on Nasdaq.
• Management and the Board have considered the potential harm to us and our stockholders should Nasdaq delist our common stock from trading.
• The Board does not intend to issue any common stock or securities convertible into common stock except on terms that the Board deems to be in the best interests of us and our stockholders.
• The Board does not intend for this transaction to be the first step in a series of plans or proposals to effect a going private transaction within the meaning of Rule 13e-3 of the Exchange Act.

Industry Context

The company's need for a reverse stock split to maintain its Nasdaq listing is a common challenge faced by small-cap biotechnology and pharmaceutical companies whose stock prices fall below exchange minimums. Maintaining a national exchange listing is critical for liquidity, investor visibility, and access to capital markets, which are vital for funding research and development in the capital-intensive biopharmaceutical industry. The mention of amended Nasdaq rules regarding reverse stock splits highlights the increasing regulatory scrutiny on companies that repeatedly use this mechanism for compliance, indicating a broader trend towards stricter listing enforcement.

Corporate Governance

Related Party Transactions

• Mr. Krishnamurthy Bhat, brother of CEO Dr. Laxminarayan Bhat, holds a 1% ownership stake and is a director of the company's Indian subsidiary, Reviva Pharmaceuticals India Private Limited.
• Seema R. Bhat, spouse of CEO Dr. Laxminarayan Bhat, is employed as Vice President for Program & Portfolio Management, with an annual base salary of $340,000 (effective Jan 1, 2025), and received a $77,500 cash bonus for fiscal year 2024. She was also granted an option to purchase 181,500 shares at an exercise price of $1.80 on February 13, 2025.
• In October 2020, 35,385 shares of Old Reviva common stock were issued to Ms. Bhat and 132,506 shares to Dr. Bhat in full satisfaction of their respective deferred salary balances.
• Vedanta R2 Partners, LP, an investment vehicle managed by certain affiliates of Chairman Parag Saxena, purchased $3,000,000.75 in pre-funded warrants and common warrants in a registered direct offering in November 2023.
• The company has entered into indemnification agreements with each of its directors and named executive officers, including a specific agreement for Parag Saxena as indemnitor of first resort.

Stakeholder Impact

• Shareholders face potential dilution from the proposed increase in authorized shares and the uncertainty of the reverse stock split's long-term effect on stock price and liquidity.
• Employees and officers may benefit from continued equity incentives and the company's efforts to maintain Nasdaq listing, which can enhance company stability and access to capital.
• Creditors may be impacted by the company's 'going concern' uncertainty and its ongoing need for capital, which could affect its ability to meet financial obligations.
• Customers and suppliers are not directly impacted by these governance and capital structure proposals, but the company's financial health and ability to fund operations could indirectly affect its long-term relationships and product development.

Next Steps

• Stockholders are urged to vote on the proposals at the Annual Meeting on December 18, 2025.
• If approved, the company intends to file the Increase in Authorized Charter Amendment as soon as practicable following the Annual Meeting.
• If the Reverse Stock Split Proposal is approved and the Board determines to implement it, the Reverse Split Charter Amendment will be filed with the Secretary of State of Delaware prior to December 31, 2026.
• The company will continue to require additional capital in the near future to fund its operations.

Key Dates

Recommendation

The company faces severe financial and operational challenges, evidenced by persistent net losses, a 'going concern' warning in its audit reports, and a Nasdaq delisting threat due to a sub-$1.00 share price. While the proposed reverse stock split is a necessary step to address the listing deficiency, its long-term effectiveness is uncertain, and it introduces risks of further liquidity reduction and potential future delisting without a compliance period. The request for a substantial increase in authorized shares, though crucial for future capital, signals ongoing dilution risk for existing shareholders. The declining Total Shareholder Return further underscores poor performance. These factors collectively indicate a high-risk investment with a negative outlook, warranting a 'sell' recommendation for seasoned investors.

Keywords

Reviva Pharmaceuticals, RVPH, proxy statement, annual meeting, reverse stock split, authorized shares, Nasdaq listing, delisting risk, corporate governance, executive compensation, auditor ratification, biopharmaceutical, shareholder vote, going concern, dilution